Amid growing concern about litigation over Vioxx, the painkiller yanked off the market, Merck & Co. shares fell nearly 10% and Standard & Poor’s Rating Services placed the company’s triple-A corporate credit and senior unsecured debt rating on watch with negative implications.

Investors’ worries about the litigation grew after an article in yesterday’s Wall Street Journal reported 1 that e-mails, memos and other internal documents suggest that company officials fought to keep safety concerns from destroying the drug’s commercial prospects. With annual sales of $2.5 billion, Vioxx last year accounted for about 11% of

Merck’s overall revenue.

In September, Merck withdrew Vioxx after a company-sponsored study found a doubling of the risk of heart attack or stroke for patients who took the painkiller for more than 18 months. Merck had described that data as "unexpected." But the internal documents suggest the company became aware of the drug’s problems years ago.

The documents are part of suits filed against Merck since 2001 on behalf of people who had heart attacks or strokes after taking Vioxx. At least 300 such lawsuits have been filed across the country, according to the company, and thousands more are being prepared in the wake of the withdrawal. More than 20 million Americans have taken Vioxx since the painkiller was introduced in 1999.

Merck reiterated comments from its Friday news release in which it warned that documents "will be deliberately presented out of context to advance the interest" of plaintiffs. The company has declined to talk specifically about the documents, citing the litigation and a court-protective order, but has said it has acted appropriately and

responsibly.

Merck’s stock price fell $3.03, or 9.7% to $28.28 yesterday in 4 p.m. New York Stock Exchange composite trading. Merck’s stock price has fallen 37% since the day before the Vioxx news, wiping out $36 billion in market capitalization.

Prudential Equity Group downgraded Merck’s stock to "neutral weight" from "over weight" and lowered its stockprice target to $33 from $37. Tim Anderson, a Prudential analyst, wrote in a report that the positive news in Merck’s drug pipeline "will likely get lost in the negativism from ongoing Vioxx coverage."

Meanwhile, plaintiffs attorneys are moving to make more Merck documents public, according to Christopher Seeger, ofNew York law firm Seeger Weiss LLP, who is leading the Vioxx litigation in New Jersey state court. Merck should "stop hiding behind the protective order that they are insisting on and allow everybody to draw their

own conclusions about the documents," Mr. Seeger said.

Plaintiffs attorneys have also been contacted by Sen. Charles Grassley, head of the Senate Finance Committee, to provide internal Merck documents about Vioxx. Andy Birchfield, who has 58 cases filed in six states, spent 31/2 hours talking with Sen. Grassley staffers yesterday and also provided the office with internal Merck documents.

The Senate Finance Committee is examining the conduct of Merck and the Food and Drug Administration in their handling of Vioxx, and last week committee investigators met with Merck attorneys and representatives. Committee Chairman Grassley, an Iowa Republican, has written to Merck asking for a broad list of information, including

records of its interactions with the FDA and of all trials the company did with Vioxx inside the U.S. and overseas.

"I intend to obtain answers and context from Merck on Vioxx," Sen. Grassley said in a statement. "Millions of Americans deserve an explanation from Merck and the FDA about why this dangerous drug was on the market for so long, apparently without adequate warnings about its risks."

Mr. Birchfield said his Vioxx case in federal court in Birmingham was scheduled to go to trial in December, but now is "up in the air"; Merck has requested that all federal court Vioxx cases be consolidated into one court under one judge.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

Best for clients

Great firm. Supports the community. They want what is best for their clients.

—Jennifer